Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells - PubMed
Affiliations
- PMID: 1532331
Review
Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells
E Eigenbrodt et al. Crit Rev Oncog. 1992.
Abstract
As a common characteristic of tumor cells, as well as of normal proliferating cells in the G1-phase of cell cycle, one finds constitutive high levels of all the glycolytic metabolites arising between glucose 6-phosphate and phosphoenolpyruvate. Thus, it is that the phosphometabolites fructose 1,6-bisphosphate, ribose 5-P, P-ribose-PP, NAD, GTP, CTO, UTP, UDP-glucose, glycerol 3-P, glycerol phosphocholine and glycerol phosphoethanolamine are useful in the 31P-nuclear magnetic resonance (NMR) detection of solid tumors in animals and man. This expansion of phosphometabolites is achieved during tumor formation as a result of reductions in levels of enzymes degrading phosphometabolites, owing to the decline in the glycerol 3-P hydrogen shuttle, and as a consequence of alterations in the glycolytic isoenzyme equipment. Tumor cells typically express a particular isoenzyme of pyruvate kinase called type M2 (K) at high levels. This isoenzyme is subject to a complex regulation by amino acids, by fructose 1,6-bisphosphate, and by hormonal- and oncogene-dependent phosphorylation. Pyruvate kinase type M2 is a substrate for the oncogene encoded PP60v-src-tyrosine kinase. A drastic decrease in the affinity for its substrate phosphoenolpyruvate found after transformation by the src-oncogene can be explained as a consequence of the phosphorylation of pyruvate kinase in serine and tyrosine. These phosphorylations induce the breakdown of tetrameric pyruvate kinase to the trimeric and dimeric forms. Unlike the tetrameric form, the dimeric form as a low affinity for phosphoenolpyruvate. Partial inactivation of pyruvate kinase and enolase on the one hand, and a hyperactivation of hexokinase and phosphofructokinase on the other hand, lead to an expansion of all metabolites. Only when these metabolites attain high levels, thereby assuring a sufficient supply of metabolites for RNA, DNA, lipid, and complex carbohydrate synthesis, can cell proliferation proceed. This accumulation of metabolites in the G1-phase cells has been termed a "metabolic budget system" because it senses not only the actual nutrient levels, but also the supply over a period of time. Monoclonal antibodies specific for the dimeric form of pyruvate kinase type M2 can be used for the immunohistological detection of tumor cells. The amount of the dimeric form in tumor cells closely correlates with the degree of malignancy and can be used for a nonspecific detection of tumors based on assays performed with patient's plasma.
Similar articles
-
Pyruvate kinase type M2: a crossroad in the tumor metabolome.
Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E. Mazurek S, et al. Br J Nutr. 2002 Jan;87 Suppl 1:S23-9. Br J Nutr. 2002. PMID: 11895152 Review.
-
Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW, Petri E, Bichler KH, Feil G. Wechsel HW, et al. Anticancer Res. 1999 Jul-Aug;19(4A):2583-90. Anticancer Res. 1999. PMID: 10470199
-
Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.
Mazurek S. Mazurek S. Int J Biochem Cell Biol. 2011 Jul;43(7):969-80. doi: 10.1016/j.biocel.2010.02.005. Epub 2010 Feb 13. Int J Biochem Cell Biol. 2011. PMID: 20156581 Review.
-
Mazurek S, Eigenbrodt E. Mazurek S, et al. Anticancer Res. 2003 Mar-Apr;23(2A):1149-54. Anticancer Res. 2003. PMID: 12820363
-
Mazurek S, Zwerschke W, Jansen-Dürr P, Eigenbrodt E. Mazurek S, et al. Oncogene. 2001 Oct 18;20(47):6891-8. doi: 10.1038/sj.onc.1204792. Oncogene. 2001. PMID: 11687968
Cited by
-
Suburu J, Chen YQ. Suburu J, et al. Prostaglandins Other Lipid Mediat. 2012 May;98(1-2):1-10. doi: 10.1016/j.prostaglandins.2012.03.003. Epub 2012 Apr 5. Prostaglandins Other Lipid Mediat. 2012. PMID: 22503963 Free PMC article. Review.
-
Sun X, Yao L, Liang H, Wang D, He Y, Wei Y, Ye L, Wang K, Li L, Chen J, Zhang CY, Xu G, Wang F, Zen K. Sun X, et al. Mucosal Immunol. 2019 Nov;12(6):1280-1290. doi: 10.1038/s41385-019-0197-6. Epub 2019 Aug 28. Mucosal Immunol. 2019. PMID: 31462699
-
Metabolic flux and the regulation of mammalian cell growth.
Locasale JW, Cantley LC. Locasale JW, et al. Cell Metab. 2011 Oct 5;14(4):443-51. doi: 10.1016/j.cmet.2011.07.014. Cell Metab. 2011. PMID: 21982705 Free PMC article. Review.
-
Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy.
Gupta S, Roy A, Dwarakanath BS. Gupta S, et al. Front Oncol. 2017 Apr 12;7:68. doi: 10.3389/fonc.2017.00068. eCollection 2017. Front Oncol. 2017. PMID: 28447025 Free PMC article. Review.
-
Non-metabolic enzyme function of pyruvate kinase M2 in breast cancer.
Jemal M, Getinet M, Amare GA, Tegegne BA, Baylie T, Mengistu EF, Osman EE, Chura Waritu N, Adugna A. Jemal M, et al. Front Oncol. 2024 Oct 1;14:1450325. doi: 10.3389/fonc.2024.1450325. eCollection 2024. Front Oncol. 2024. PMID: 39411137 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous